BRPI1013991A2 - anticorpo monoclonal para o diagnóstico e tratamento de doenças cardiovasculares, composição farmacêutica, conjunto de reativos úteis no diagnóstico de lesões ateroscleróticas, e, uso de um anticorpo - Google Patents

anticorpo monoclonal para o diagnóstico e tratamento de doenças cardiovasculares, composição farmacêutica, conjunto de reativos úteis no diagnóstico de lesões ateroscleróticas, e, uso de um anticorpo

Info

Publication number
BRPI1013991A2
BRPI1013991A2 BRPI1013991A BRPI1013991A BRPI1013991A2 BR PI1013991 A2 BRPI1013991 A2 BR PI1013991A2 BR PI1013991 A BRPI1013991 A BR PI1013991A BR PI1013991 A BRPI1013991 A BR PI1013991A BR PI1013991 A2 BRPI1013991 A2 BR PI1013991A2
Authority
BR
Brazil
Prior art keywords
diagnosis
antibody
treatment
pharmaceutical composition
cardiovascular disease
Prior art date
Application number
BRPI1013991A
Other languages
English (en)
Inventor
Alejandro Lopez Requena
Ana María Vazquez Lopez
Cristina María Mateo De Acosta Del Rio
Victor Brito Navarro
Yosdel Soto Lopez
Yuniel Fernandez Marrero
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42355373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013991(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BRPI1013991A2 publication Critical patent/BRPI1013991A2/pt
Publication of BRPI1013991B1 publication Critical patent/BRPI1013991B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1013991-5A 2009-05-04 2010-05-03 Anticorpo monoclonal, composição farmacêutica, conjunto de reativos úteis no diagnóstico de lesões ateroscleróticas, e, uso de um anticorpo BRPI1013991B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2009-0071 2009-05-04
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
PCT/CU2010/000002 WO2010127642A1 (es) 2009-05-04 2010-05-03 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Publications (2)

Publication Number Publication Date
BRPI1013991A2 true BRPI1013991A2 (pt) 2016-04-05
BRPI1013991B1 BRPI1013991B1 (pt) 2021-08-31

Family

ID=42355373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013991-5A BRPI1013991B1 (pt) 2009-05-04 2010-05-03 Anticorpo monoclonal, composição farmacêutica, conjunto de reativos úteis no diagnóstico de lesões ateroscleróticas, e, uso de um anticorpo

Country Status (20)

Country Link
US (1) US8470322B2 (pt)
EP (1) EP2428521B1 (pt)
JP (1) JP5354823B2 (pt)
KR (1) KR101374263B1 (pt)
CN (1) CN102414222B (pt)
AR (1) AR076495A1 (pt)
AU (1) AU2010244859B2 (pt)
BR (1) BRPI1013991B1 (pt)
CA (1) CA2758994C (pt)
CL (1) CL2010000413A1 (pt)
CU (1) CU23736A1 (pt)
ES (1) ES2656849T3 (pt)
MX (1) MX2011011665A (pt)
MY (1) MY158954A (pt)
PE (1) PE20100808A1 (pt)
RU (1) RU2502744C2 (pt)
SG (1) SG175849A1 (pt)
TW (1) TWI424852B (pt)
WO (1) WO2010127642A1 (pt)
ZA (1) ZA201108832B (pt)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US20020018808A1 (en) 1990-12-10 2002-02-14 Alving Carl R. Vaccines against sterols
US5541296A (en) 1991-08-30 1996-07-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Monocyte adhesion protein and monoclonal antibody thereto
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
JP4315257B2 (ja) * 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
AU721729B2 (en) 1996-05-01 2000-07-13 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6291437B1 (en) 1996-08-14 2001-09-18 The Wistar Institute Of Anatomy And Biology Methods and compositions for retarding the development of atherosclerotic lesions
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU3817899A (en) 1998-04-15 1999-11-01 Inserm Therapy of atherosclerosis
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
MXPA02008616A (es) 2000-03-03 2003-02-24 Smithkline Beecham Biolog Vacuna para el tratamiento de la arterosclerosis.
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0305790D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
GB0305793D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
WO2004091520A2 (en) 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
ATE463254T1 (de) 2004-04-15 2010-04-15 Athera Biotechnologies Ab Antikörper gegen phosphorylcholinkonjugate
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Also Published As

Publication number Publication date
AU2010244859B2 (en) 2014-05-29
JP5354823B2 (ja) 2013-11-27
KR101374263B1 (ko) 2014-03-13
ES2656849T3 (es) 2018-02-28
EP2428521B1 (en) 2018-01-03
CU23736A1 (es) 2011-11-15
CA2758994C (en) 2015-07-21
MY158954A (en) 2016-11-30
PE20100808A1 (es) 2011-01-07
JP2012526056A (ja) 2012-10-25
TW201103559A (en) 2011-02-01
CN102414222B (zh) 2014-07-16
CA2758994A1 (en) 2010-11-11
WO2010127642A1 (es) 2010-11-11
ZA201108832B (en) 2012-08-29
AU2010244859A1 (en) 2011-12-08
US20120121605A1 (en) 2012-05-17
HK1168362A1 (en) 2012-12-28
CN102414222A (zh) 2012-04-11
TWI424852B (zh) 2014-02-01
WO2010127642A9 (es) 2011-03-24
RU2502744C2 (ru) 2013-12-27
CL2010000413A1 (es) 2011-02-25
BRPI1013991B1 (pt) 2021-08-31
RU2011149252A (ru) 2013-06-10
US8470322B2 (en) 2013-06-25
EP2428521A1 (en) 2012-03-14
SG175849A1 (en) 2011-12-29
KR20120016055A (ko) 2012-02-22
MX2011011665A (es) 2012-06-01
AR076495A1 (es) 2011-06-15

Similar Documents

Publication Publication Date Title
CY2025024I2 (el) Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
BR112012003759A2 (pt) "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."
BRPI0822092A2 (pt) Dispositivo sensor microeletrônico para o exame de partículas alvo, método para o exame das partículas alvo, e, uso do dispositivo sensor microeletrônico
HUE037642T2 (hu) Humán cd134 (ox40) humán monoklonális antitest és eljárások annak elõállítására és alkalmazására
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
IL287311A (en) Antibodies and processes for preparing the same
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
BRPI0922885A2 (pt) anticorpos humanos de alta afinidade para a pcsk9.
IL193904A0 (en) Anti-igf-1r human monoclonal antibody formulation
HUE058876T2 (hu) Anti-GM-CSF antitestek és felhasználásuk
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI0916366A2 (pt) exame diagnóstico de anticorpo
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
CL2011000711A1 (es) Anticuerpo monoclonal que se une al receptor de regulacion negativa (nrr) de notch2; formulacion farmaceutica que lo comprende; y su uso para tratar una enfermedad maligna por celula b o melanoma.
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2529 DE 25/06/2019 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.